Literature DB >> 3705143

The incidence of development of irregular red cell antibodies in patients with sickle cell anemia.

S Sarnaik, J Schornack, J M Lusher.   

Abstract

Two hundred and forty-five patients with SS hemoglobinopathy were screened for alloimmunization; they had all been transfused previously. Their median age was 10 years. Nineteen patients (7.75%) were found to be sensitized to various red cell antigens. The median number of transfusions received by sensitized patients was 23 compared to three in the unsensitized group, indicating an increased risk with more transfusion exposures. Thirteen sensitized patients were re-exposed to transfusion and four (30%) developed new alloantibodies. Once immunized, the risk of developing more alloantibodies on re-exposure did not increase with increasing number of exposures. The most frequently observed alloantibody was anti-K, accounting for 38 percent of all instances. Anti-Lea and -Leb were next in frequency (24%); Rh antibodies were seen in 14 percent of cases. Children with sickle cell anemia who were multiply transfused had a low frequency of alloimmunization. Responders had an increased rate of further sensitization which did not increase with number of subsequent exposures. Phenotypically matched blood is probably not warranted in most patients receiving transfusions for sickle cell anemia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3705143     DOI: 10.1046/j.1537-2995.1986.26386209381.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  15 in total

1.  Immune Regulation of sickle Cell Alloimmunization.

Authors:  Karina Yazdanbakhsh; Beth H Shaz; Christopher D Hillyer
Journal:  ISBT Sci Ser       Date:  2016-11-15

Review 2.  Sickle cell diseases: current therapeutic options and potential pitfalls in preventive therapy for transcranial Doppler abnormalities.

Authors:  Sharada A Sarnaik
Journal:  Pediatr Radiol       Date:  2005-02-10

Review 3.  Transfusion in Haemoglobinopathies: Review and recommendations for local blood banks and transfusion services in Oman.

Authors:  Arwa Z Al-Riyami; Shahina Daar
Journal:  Sultan Qaboos Univ Med J       Date:  2018-04-04

Review 4.  Genetics of transfusion recipient alloimmunization: can clues from susceptibility to autoimmunity pave the way?

Authors:  Zohreh Tatari-Calderone; Naomi L C Luban; Stanislav Vukmanovic
Journal:  Transfus Med Hemother       Date:  2014-11-17       Impact factor: 3.747

Review 5.  The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders.

Authors:  Eric A Gehrie; Christopher A Tormey
Journal:  Transfus Med Hemother       Date:  2014-11-17       Impact factor: 3.747

6.  Drug-loaded sickle cells programmed ex vivo for delayed hemolysis target hypoxic tumor microvessels and augment tumor drug delivery.

Authors:  Se-woon Choe; David S Terman; Angela E Rivers; Jose Rivera; Richard Lottenberg; Brian S Sorg
Journal:  J Control Release       Date:  2013-07-18       Impact factor: 9.776

7.  Regulatory B-cell compartment in transfused alloimmunized and non-alloimmunized patients with sickle cell disease.

Authors:  Weili Bao; Hui Zhong; Deepa Manwani; Ljiljana Vasovic; Joan Uehlinger; Margaret T Lee; Sujit Sheth; Patricia Shi; Karina Yazdanbakhsh
Journal:  Am J Hematol       Date:  2013-06-20       Impact factor: 10.047

8.  Patients with sickle cell anemia on simple chronic transfusion protocol show sex differences for hemodynamic and hematologic responses to transfusion.

Authors:  Jon A Detterich; Suvimol Sangkatumvong; Roberta Kato; Ani Dongelyan; Adam Bush; Michael Khoo; Herbert J Meiselman; Thomas D Coates; John C Wood
Journal:  Transfusion       Date:  2012-11-26       Impact factor: 3.157

9.  Red Blood Cell Alloimmunization in Sickle Cell Disease Patients in Tanzania.

Authors:  E Meda; P M Magesa; T Marlow; C Reid; D J Roberts; J Makani
Journal:  East Afr J Public Health       Date:  2014

Review 10.  Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management.

Authors:  Karina Yazdanbakhsh; Russell E Ware; France Noizat-Pirenne
Journal:  Blood       Date:  2012-05-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.